Advertisement

Glycemic Markers and Heart Failure Subtypes: The Multi-Ethnic Study of Atherosclerosis (MESA)

      Highlights

      • Glycemic dysregulation and its markers are precursors of heart failure (HF) .
      • Diabetes, fasting glucose, and hemoglobin A1c were similarly associated with high risks of both HF subtypes.
      • Greater insulin resistance and hyperinsulinemia were not significantly associated with either HF subtype.

      Abstract

      Background

      Although diabetes increases heart failure (HF) risk, it is unclear how various dysglycemia markers (hemoglobin A1C [HbA1C], fasting plasma glucose [FPG], homeostasis model assessment of insulin resistance, and fasting insulin) are associated with HF subtypes (HF with preserved ejection fraction [HFpEF] and HF with reduced ejection fraction [HFrEF]). We assessed the relation of markers of dysglycemia and risks of HFpEF and HFrEF.

      Methods and Results

      We included 6688 adults without prevalent cardiovascular disease who attended the first MESA visit (2000–2002) and were followed for incident hospitalized HF (HFpEF or HFrEF). Association of glycemic markers and status (normoglycemia, prediabetes, diabetes) with HFpEF and HFrEF were evaluated using adjusted Cox models. Over a median follow-up of 14.9 years, there were 356 HF events (145 HFpEF, 173 HFrEF, and 38 indeterminate HF events). Diabetes status conferred higher risks of HFpEF (hazard ratio [HR] 1.85, 95% confidence interval [CI] 1.57–2.68) and HFrEF (HR 2.02, 95% CI 1.38–2.97) compared with normoglycemia. Higher levels of FPG (126 mg/dL) and HbA1C (≥6.5%) were associated with similarly higher risks of HFpEF (HR for FPG 1.96, 95% CI 1.21–3.17; HR for HbA1C 2.00, 95% CI 1.20–3.31) and HFrEF (HR for FPG 1.84, 95% CI 1.18–2.88; HR for HbA1C 1.99, 95% CI 1.28–3.09) compared with reference values. Prediabetic range HbA1C (5.7%–6.4%) or FPG (100%–125 mg/dL), homeostasis model assessment of insulin resistance, and fasting insulin were not significantly associated with HFpEF or HFrEF.

      Conclusions

      Among community-dwelling individuals, HbA1C and FPG in the diabetes range were each associated with higher risks of HFpEF and HFrEF, with similar magnitudes of their associations.

      Lay Abstract

      Heart failure (HF) has 2 major subtypes (the heart's inability to pump or to fill up). Diabetes is known to increase HF risk, but its effects and that of markers of high glucose levels (fasting blood glucose and hemoglobin A1C) on the occurrence of HF subtypes remains unknown. Among 6688 adults without known cardiovascular disease followed for nearly 15 years, diabetes conferred significantly higher risks of both HF types, compared with those with normal blood glucose levels. Higher levels of fasting blood glucose and hemoglobin A1C were similarly associated with higher risks of both types of HF.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Cardiac Failure
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Virani SS
        • Alonso A
        • Aparicio HJ
        • et al.
        Heart disease and stroke statistics—2021 update: a report from the American Heart Association.
        Circulation. 2021; 143: e254-e743
        • Menke A
        • Casagrande S
        • Geiss L
        • Cowie CC.
        Prevalence of and trends in diabetes among adults in the United States, 1988-2012.
        JAMA. 2015; 314: 1021-1029
        • Ohkuma T
        • Komita Y
        • Peters SAE
        • Woodward M.
        Diabetes as a risk factor for heart failure in women and men: a systematic review and meta-analysis of 47 cohorts including 12 million individuals.
        Diabetologia. 2019; 62: 1550-1560
        • Aune D
        • Schlesinger S
        • Neuenschwander M
        • et al.
        Diabetes mellitus, blood glucose and the risk of heart failure: a systematic review and meta-analysis of prospective studies.
        Nutr Metab Cardiovasc Dis. 2018; 28: 1081-1091
        • Bugger H
        • Abel ED.
        Molecular mechanisms of diabetic cardiomyopathy.
        Diabetologia. 2014; 57: 660-671
        • Jia G
        • Hill MA
        • Sowers JR.
        Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity.
        Circ Res. 2018; 122: 624-638
        • Kannel WB
        • Hjortland M
        • Castelli WP.
        Role of diabetes in congestive heart failure: the Framingham Study.
        Am J Cardiol. 1974; 34: 29-34
        • Barzilay JI
        • Kronmal RA
        • Gottdiener JS
        • et al.
        The association of fasting glucose levels with congestive heart failure in diabetic adults ≥65 years: the Cardiovascular Health Study.
        J Am Coll Cardiol. 2004; 43: 2236-2241
        • Matsushita K
        • Blecker S
        • Pazin-Filho A
        • et al.
        The association of hemoglobin A1c with incident heart failure among people without diabetes: the Atherosclerosis Risk in Communities study.
        Diabetes. 2010; 59: 2020-2026
        • Pazin-Filho A
        • Kottgen A
        • Bertoni AG
        • et al.
        HbA 1c as a risk factor for heart failure in persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) study.
        Diabetologia. 2008; 51: 2197-2204
        • De Simone G
        • Devereux RB
        • Chinali M
        • et al.
        Diabetes and incident heart failure in hypertensive and normotensive participants of the Strong Heart Study.
        J Hypertens. 2010; 28: 353-360
        • de Boer RA
        • Nayor M
        • deFilippi CR
        • et al.
        Association of cardiovascular biomarkers with incident heart failure with preserved and reduced ejection fraction.
        JAMA Cardiol. 2018; 3: 215-224
        • Ho JE
        • Enserro D
        • Brouwers FP
        • et al.
        Predicting heart failure with preserved and reduced ejection fraction: the International Collaboration on Heart Failure Inftypes.
        . Circ Heart Fail. 2016; 9: 10
        • Paulus WJ
        • Dal Canto E.
        Distinct myocardial targets for diabetes therapy in heart failure with preserved or reduced ejection fraction.
        JACC Heart Fail. 2018; 6 (–-7)
        • Echouffo-Tcheugui JB
        • Xu H
        • DeVore AD
        • et al.
        Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: findings from Get With The Guidelines–Heart Failure registry.
        Am Heart J. 2016; 182: 9-20
        • van Heerebeek L
        • Hamdani N
        • Handoko ML
        • et al.
        Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension.
        Circulation. 2008; 117: 43-51
        • Bild DE
        • Bluemke DA
        • Burke GL
        • et al.
        Multi-Ethnic Study of Atherosclerosis: objectives and design.
        Am J Epidemiol. 2002; 156: 871-881
        • Matthews DR
        • Hosker JP
        • Rudenski AS
        • Naylor BA
        • Treacher DF
        • Turner RC
        Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.
        Diabetologia. 1985; 28: 412-419
        • American Diabetes Association
        Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes-2021.
        Diabetes Care. 2021; 44: S15-S33
        • Rao VN
        • Zhao D
        • Allison MA
        • et al.
        Adiposity and incident heart failure and its subtypes: MESA (Multi-Ethnic Study of Atherosclerosis).
        JACC Heart Fail. 2018; 6: 999-1007
        • Levey AS
        • Stevens LA
        • Schmid CH
        • et al.
        A new equation to estimate glomerular filtration rate.
        Ann Intern Med. 2009; 150: 604-612
        • Vella CA
        • Allison MA
        • Cushman M
        • et al.
        Physical activity and adiposity-related inflammation: the MESA.
        Med Sci Sports Exerc. 2017; 49: 915-921
        • Fine JP
        • Gray RJ.
        A proportional hazards model for the subdistribution of a competing risk.
        J Am Stat Assoc. 1999; 94: 496-509
        • Kalogeropoulos A
        • Georgiopoulou V
        • Harris TB
        • et al.
        Glycemic status and incident heart failure in elderly without history of diabetes mellitus: the Health, Aging, and Body Composition Study.
        J Card Fail. 2009; 15: 593-599
        • Savji N
        • Meijers WC
        • Bartz TM
        • et al.
        The association of obesity and cardiometabolic traits with Incident HFpEF and HFrEF.
        JACC Heart Fail. 2018; 6: 701-709
        • Echouffo-Tcheugui JB
        • Mwasongwe SE
        • Musani SK
        • et al.
        Dysglycemia and incident heart failure among blacks: the Jackson Heart Study.
        Am Heart J. 2021; 245: 1-9
        • Devereux RB
        • Roman MJ
        • Paranicas M
        • et al.
        Impact of diabetes on cardiac structure and function: the Strong Heart Study.
        Circulation. 2000; 101: 2271-2276
        • Skali H
        • Shah A
        • Gupta DK
        • et al.
        Cardiac structure and function across the glycemic spectrum in elderly men and women free of prevalent heart disease: the Atherosclerosis Risk in the Community Study.
        Circ Heart Fail. 2015; 8: 448-454
        • Zoppini G
        • Bergamini C
        • Mantovani A
        • et al.
        The E/e’ ratio difference between subjects with type 2 diabetes and controls. A metaanalysis of clinical studies.
        PLoS One. 2018; 13e0209794
        • Banerjee D
        • Biggs ML
        • Mercer L
        • et al.
        Insulin resistance and risk of incident heart failure cardiovascular health study.
        Circ Heart Fail. 2013; 6: 364-370
        • Vardeny O
        • Gupta DK
        • Claggett B
        • et al.
        Insulin resistance and incident heart failure. The ARIC Study (Atherosclerosis Risk in Communities).
        JACC Heart Fail. 2013; 1: 531-536
        • Ingelsson E
        • Sundström J
        • Ärnlöv J
        • Zethelius B
        • Lind L
        Insulin resistance and risk of congestive heart failure.
        JAMA. 2005; 294: 334-341
        • Boudina S
        • Abel ED
        Diabetic cardiomyopathy, causes and effects.
        Rev Endocr Metab Disord. 2010; 11: 31-39
        • Zelniker TA
        • Wiviott SD
        • Raz I
        • et al.
        SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
        Lancet. 2019; 393: 31-39
        • Zannad F
        • Ferreira JP
        • Pocock SJ
        • et al.
        SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
        Lancet. 2020; 396: 819-829
        • McGuire DK
        • Shih WJ
        • Cosentino F
        • et al.
        Association of sglt2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis.
        JAMA Cardiol. 2021; 6: 148-158
        • Anker SD
        • Butler J
        • Filippatos G
        • et al.
        Empagliflozin in heart failure with a preserved ejection fraction.
        N Engl J Med. 2021; 385: 1451-1461
        • Packer M
        • Butler J
        • Zannad F
        • et al.
        Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: EMPEROR-Preserved Trial.
        Circulation. 2021; 144: 1284-1294
        • Yancy CW
        • Jessup M
        • Bozkurt B
        • et al.
        2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
        J Am Coll Cardiol. 2013; 62: e147-e239
        • Echouffo-Tcheugui JB
        • Selvin E.
        Pre-diabetes and what it means: the epidemiological evidence.
        Annu Rev Public Health. 2021; 42: 59-77
        • Ho JE
        • Lyass A
        • Lee DS
        • et al.
        Predictors of new-onset heart failure differences in preserved versus reduced ejection fraction.
        Circ Heart Fail. 2013; 6: 279-286
        • Bozkurt B
        • Coats A
        • Tsutsui H.
        Universal definition and classification of heart failure.
        J Card Fail. 2021 Feb 7; (S1071-9164(21)00050-6)
        • Meijnikman AS
        • De Block CEM
        • Dirinck E
        • et al.
        Not performing an OGTT results in significant underdiagnosis of (pre)diabetes in a high risk adult Caucasian population.
        Int J Obesity. 2017; 41: 1615-1620
        • Muniyappa R
        • Lee S
        • Chen H
        • Quon MJ.
        Current approaches for assessing insulin sensitivity and resistance in vivo: Advantages, limitations, and appropriate usage.
        Am J Physiol Endocrinol Metab. 2008; 294: E15-E26